IL2 and systemic lupus erythematosus: These observations encouraged clinical studies using low-dose IL-2 as a therapy in SLE patients, which resulted in an expansion of peripheral Tregs expressing high levels of CD25, retained their suppressive capacity and reduced disease activity [172,179].